Peter Sasieni

Professor Peter Sasieni is a Professor of Cancer Epidemiology and Co-Lead of the Centre for Cancer Screening, Prevention and Early Diagnosis at Queen Mary University of London (QMUL). He directs the Cancer Research UK Cancer Prevention Trials Unit and holds leadership roles in major grants including the NHS-Galleri trial and BEST4 platform. His research focuses on cancer screening technologies, HPV-related cancers, and oesophageal adenocarcinoma through clinical trials and epidemiological studies. He is a Fellow of the Academy of Medical Sciences and recipient of the 2023 Don Listwin Award for contributions to early cancer detection.

Key research interests include multi-cancer early detection via liquid biopsies, cervical cancer elimination strategies, and the Cytosponge device for oesophageal screening. He leads trials such as NHS Galleri (multi-cancer blood tests), BEST4-Surveillance, and FIT4Lynch. His statistical expertise includes clinical trial design and causal inference methodologies.

Notable achievements include demonstrating the national HPV vaccination program's impact on cervical cancer reduction and pioneering non-invasive screening tools. He collaborates with institutions like the Francis Crick Institute and University of Cambridge, contributing to both UK and global cancer research agendas.

• Awards: Don Listwin Award (2023), Academy of Medical Sciences Fellowship
• Key Trials: NHS Galleri, BEST4, Cytosponge, YORKE-SURe, FIT4Lynch
• Grants: CRUK-NIHR, Yorkshire Cancer Research, NIHR School for Primary Care
• Labs/Teams: Cancer Prevention Trials Unit, Centre for Cancer Screening